3.280NOK+0.15%Mkt Cap: 1.07B NOKP/E: —Last update: 2026-05-22
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.07B NOK
Enterprise Value1.01B NOK
Revenue (TTM)453.00K NOK
Gross Profit453.00K NOK
Net Income (TTM)-12.24M NOK
Revenue/Share0.0010 NOK
Last Price3.280 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees59
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010714785
Valuation
P/E (Trailing)—
P/E (Forward)-4.12
PEG—
EV/EBITDA-36.32
EV/Revenue2233.33
P/S2360.79
P/B1.27
EPS (TTM)-0.37
EPS (Forward)-0.79
52W Range
3.16588% of range3.295
52W High3.295 NOK
52W Low3.165 NOK
Profitability
Gross Margin100.00%
Oper. Margin-6310.82%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-13.37%
ROA-12.25%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.46M NOK
CapEx (TTM)38.00K NOK
FCF Margin-4144.15%
FCF Yield-1.75%
Net Debt-57.74M NOK
Net Debt/EBITDA2.07
Balance Sheet
Debt/Equity0.03
Current Ratio9.99
Quick Ratio9.88
Book Value/Sh2.573 NOK
Cash/Share0.1850 NOK
Dividends
Fwd Div Rate1.000 NOK
Trail. Div Rate0.0000 NOK
Div. Yield31.60%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 27, 2025
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.500 NOK
Target Range4.500 NOK – 4.500 NOK
# Analysts1
Ownership
Shares Out.326.55M
Float169.58M
Insiders43.60%
Institutions17.83%
Technical
SMA 503.161 (+3.8%)
SMA 2002.527 (+29.8%)
Beta0.86
S&P 52W Chg27.23%
Avg Vol (30d)482.69K
Avg Vol (10d)548.94K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—